Observation of de novo bladder dysfunction under treatment with her2-neu antibodies

Urologia Internationalis

Volumn 86, Issue 1, 2011, Pages 80-84

  Hinkel, Andreas ^a,c   Strumberg, Dirk ^a   Noldus, Joachim ^a   Pannek, Jürgen ^b  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b SWISS PARAPLEGIC RESEARCH   (Switzerland)

^c FRANZISKUS HOSPITAL   (Germany)

Author keywords

Adverse drug reaction; Bladder dysfunction; Metastatic breast cancer; Trastuzumab

Indexed keywords

ANTIESTROGEN; AROMATASE INHIBITOR; TAXANE DERIVATIVE; TRASTUZUMAB;

ADULT; ARTICLE; BLADDER CAPACITY; BLADDER DYSFUNCTION; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER PATIENT; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HUMAN; KINGS HEALTH QUESTIONNAIRE; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; MICTURITION DISORDER; MULTIMODALITY CANCER THERAPY; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RATING SCALE; RETROSPECTIVE STUDY; URINARY FREQUENCY; URINARY URGENCY; URINE INCONTINENCE;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; QUESTIONNAIRES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; URINARY INCONTINENCE;

EID: 79951813060     PISSN: 00421138     EISSN: None     Source Type: Journal    
DOI: 10.1159/000317441     Document Type: Article

References (19)

1. Hudis CA: Trastuzumab - mechanism of action and use in clinical practice. N Engl J Med 2007; 357: 39-51. (Pubitemid 47026733)
2. Kelleher CJ, Cardozo LD, Khullar V, et al: A new questionnaire to assess the quality of life of urinary incontinent women. Br J Obstet Gynaecol 1997; 104: 1374-1379. (Pubitemid 27517634)
3. Irwin DE, Milsom I, Hunskaar S, et al: Population- based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 2006; 50: 1306-1314.
4. Robinson D, Cardozo LD: The role of estrogens in female lower urinary tract dysfunction. Urology 2003; 62(suppl 1):45-51. (Pubitemid 41116582)
5. Cardozo L, Lose G, McClish D, et al: A systematic review of the effects of estrogens for symptoms suggestive of overactive bladder. Acta Obstet Gynecol Scand 2004; 83: 892-897. (Pubitemid 39331534)
6. Acar D, Cayan S, Akta° S, et al: The effect of tamoxifen on bladder functions and histology, and the role of estrogen receptor beta in a rat chemical cystitis model. Neurourol Urodyn 2007; 26: 309-319.
7. Hadji P: Menopausal symptoms and adjuvant therapy-associated adverse events. Endocr Relat Cancer 2008; 15: 73-90. (Pubitemid 351449729)
8. Kuroi K, Shimozuma K: Neurotoxicity of taxanes: symptoms and quality of life assessment. Breast Cancer 2004; 11: 92-99.
9. Yarden Y: The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities. Eur J Cancer 2001; 37(suppl 4):S3-S8. (Pubitemid 32938123)
10. Smith I, Procter M, Gelber RD, et al: Twoyear follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 2007; 369: 29-36. (Pubitemid 46039831)
11. Untch M, Gelber RD, Jackisch C, et al: Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial. Ann Oncol 2008; 19: 1090-1096. (Pubitemid 351796334)
12. Johnston SR: Clinical efforts to combine endocrine agents with targeted therapies against epidermal growth factor receptor/ human epidermal growth factor receptor-2 and mammalian target of rapamycin in breast cancer. Clin Cancer Res 2006; 12: 1061s-1068s. (Pubitemid 43259844)
13. Zaczek A, Brandt B, Bielawski KP: The diverse signaling network of EGFR, HER2, HER3 and HER4 tyrosine kinase receptors and the consequences for therapeutic approaches. Histol Histopathol 2005; 20: 1005-1015. (Pubitemid 40932618)
14. Elbadawi AE, Light JK: Distinctive ultrastructural pathology of non-ulcerative interstitial cystitis: new observations and their potential significance in pathogenesis. Urol Int 1996; 56: 137-162.
15. Sun Y, Chen M, Lowentritt BH, et al: EGF and HB-EGF modulate inward potassium current in human bladder urothelial cells from normal and interstitial cystitis patients. Am J Physiol 2007; 292:C106-C114. (Pubitemid 46115124)
16. Balestreire EM, Apodaca G: Apical epidermal growth factor receptor signaling: regulation of stretch-dependent exocytosis in bladder umbrella cells. Mol Biol Cell 2007; 18: 1312-1323. (Pubitemid 46626626)
17. Erschbamer M, Pernold K, Olson L: Inhibiting epidermal growth factor receptor improves structural, locomotor, sensory, and bladder recovery from experimental spinal cord injury. J Neurosci 2007; 27: 6428-6435. (Pubitemid 46920375)
18. Bjelic-Radisic V, Dorfer M, Tamussino K, et al: Psychometric properties and validation of the German-language King's Health Questionnaire in women with stress urinary incontinence. Neurourol Urodyn 2005; 24: 63-68. (Pubitemid 40052542)
19. Bjelic-Radisic V, Dorfer M, Greimel E, et al: Quality of life and continence one year after the tension-free vaginal tape operation. Am J Obstet Gynecol 2006; 195: 1784-1788. (Pubitemid 44792655)